The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
15
Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.
200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.
National Cancer Centre Singapore
Singapore, Singapore
Amount of tracer uptake in the tumour lesions of NPC patients
The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.
Time frame: From time of tracer injection to time the scan is performed
Amount of tracer uptake in the tumour lesions of patients with EBV related cancers
The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.
Time frame: From time of tracer injection to time the scan is performed
Number of somatostatin receptors in patient biopsy samples
Time frame: Upon signing the informed consent form
Amount of somatostatin circulating tumour cells in patient blood samples
Time frame: At the time of scan
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.